Frontier Wealth Management LLC lowered its position in shares of Johnson & Johnson (NYSE:JNJ) by 2.7% in the second quarter, according to its most recent disclosure with the SEC. The institutional investor owned 42,550 shares of the company’s stock after selling 1,187 shares during the quarter. Johnson & Johnson comprises 0.9% of Frontier Wealth Management LLC’s holdings, making the stock its 27th biggest position. Frontier Wealth Management LLC’s holdings in Johnson & Johnson were worth $5,629,000 at the end of the most recent quarter.
Other institutional investors and hedge funds have also recently bought and sold shares of the company. State Street Corp grew its position in Johnson & Johnson by 4.3% in the first quarter. State Street Corp now owns 160,223,321 shares of the company’s stock valued at $19,955,806,000 after acquiring an additional 6,656,371 shares during the last quarter. BlackRock Inc. grew its position in Johnson & Johnson by 2.6% in the second quarter. BlackRock Inc. now owns 174,073,764 shares of the company’s stock valued at $23,028,219,000 after acquiring an additional 4,332,612 shares during the last quarter. Vanguard Group Inc. grew its position in Johnson & Johnson by 1.5% in the second quarter. Vanguard Group Inc. now owns 200,450,985 shares of the company’s stock valued at $26,517,661,000 after acquiring an additional 3,023,110 shares during the last quarter. Parametric Portfolio Associates LLC grew its position in Johnson & Johnson by 47.9% in the second quarter. Parametric Portfolio Associates LLC now owns 7,970,670 shares of the company’s stock valued at $1,054,433,000 after acquiring an additional 2,581,562 shares during the last quarter. Finally, Harbour Capital Advisors LLC grew its position in Johnson & Johnson by 13,327.8% in the second quarter. Harbour Capital Advisors LLC now owns 2,501,472 shares of the company’s stock valued at $18,909,000 after acquiring an additional 2,482,843 shares during the last quarter. 65.89% of the stock is owned by institutional investors.
Several analysts have recently weighed in on JNJ shares. Goldman Sachs Group cut Johnson & Johnson from a “neutral” rating to a “sell” rating and boosted their price target for the stock from $125.00 to $130.00 in a report on Wednesday, September 20th. BMO Capital Markets restated a “buy” rating and set a $145.00 price target on shares of Johnson & Johnson in a report on Friday, September 1st. Vetr upgraded Johnson & Johnson from a “sell” rating to a “hold” rating and set a $137.71 price target on the stock in a report on Monday, October 30th. Credit Suisse Group set a $154.00 price target on Johnson & Johnson and gave the stock an “outperform” rating in a report on Thursday, October 19th. Finally, UBS restated an “underweight” rating on shares of Johnson & Johnson in a report on Thursday, August 24th. Four research analysts have rated the stock with a sell rating, seven have given a hold rating and eleven have given a buy rating to the company’s stock. Johnson & Johnson has a consensus rating of “Hold” and an average price target of $144.59.
Shares of Johnson & Johnson (NYSE JNJ) traded up $0.58 on Monday, reaching $140.59. The company’s stock had a trading volume of 5,101,300 shares, compared to its average volume of 5,868,289. Johnson & Johnson has a 12-month low of $110.76 and a 12-month high of $144.35. The company has a debt-to-equity ratio of 0.36, a quick ratio of 1.02 and a current ratio of 1.32. The firm has a market capitalization of $377,697.84, a price-to-earnings ratio of 19.69, a PEG ratio of 2.86 and a beta of 0.80.
Johnson & Johnson (NYSE:JNJ) last issued its earnings results on Tuesday, October 17th. The company reported $1.90 earnings per share for the quarter, topping analysts’ consensus estimates of $1.80 by $0.10. Johnson & Johnson had a return on equity of 27.38% and a net margin of 21.28%. The company had revenue of $19.65 billion for the quarter, compared to analyst estimates of $19.29 billion. During the same period in the prior year, the firm earned $1.68 earnings per share. Johnson & Johnson’s revenue for the quarter was up 10.3% on a year-over-year basis. equities research analysts expect that Johnson & Johnson will post 7.28 EPS for the current fiscal year.
The company also recently announced a quarterly dividend, which will be paid on Tuesday, December 12th. Stockholders of record on Tuesday, November 28th will be given a dividend of $0.84 per share. This represents a $3.36 dividend on an annualized basis and a dividend yield of 2.39%. The ex-dividend date of this dividend is Monday, November 27th. Johnson & Johnson’s payout ratio is 58.33%.
ILLEGAL ACTIVITY NOTICE: This story was first published by Zolmax and is owned by of Zolmax. If you are reading this story on another website, it was stolen and reposted in violation of US and international copyright and trademark legislation. The legal version of this story can be read at https://zolmax.com/investing/frontier-wealth-management-llc-reduces-stake-in-johnson-johnson-jnj/1838006.html.
Johnson & Johnson Profile
Johnson & Johnson is a holding company, which is engaged in the research and development, manufacture and sale of a range of products in the healthcare field. It operates through three segments: Consumer, Pharmaceutical and Medical Devices. Its primary focus is products related to human health and well-being.
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.